






# Risk Factors and Profile of Congenital Abnormalities in Central Morocco

Soukaina Kannane <sup>1,\*</sup>, Ilham Atif <sup>1</sup>, Samia Boussaa <sup>2</sup>, Jalal Ouirari <sup>3</sup>, Oulaid Touloun <sup>1</sup>

<sup>1</sup> Polyvalent Team of Research and Development (PTRD), Faculty of Polydisciplinary, Sultan Moulay Slimane University, 23000, Beni Mellal, Morocco

<sup>2</sup> Higher Institute of Nursing and Health Techniques, Ministry of Health and Social Protection, 10000, Rabat, Morocco

<sup>3</sup> Laboratory of Biotechnology & Sustainable Development of Natural Resources, Faculty of Polydisciplinary, Sultan Moulay Slimane University, 23000, Beni Mellal, Morocco

\*Corresponding author: Polyvalent Team of Research and Development (PTRD), Faculty of Polydisciplinary, Sultan Moulay Slimane University, 23000, Beni Mellal, Morocco. Email: kannane.soukaina@gmail.com

Received 2023 June 13; Revised 2024 July 12; Accepted 2024 July 15.

## Abstract

**Background:** In Morocco, there is no official data on the prevalence of congenital abnormalities (CAs). Available data are mostly derived from hospital-based retrospective epidemiological analyses.

**Objectives:** This study aims to describe the prevalence, distribution, and risk factors of CAs in the Beni Mellal-Khenifra region of central Morocco.

**Methods:** Epidemiological data were obtained from delivery files of 163,842 births recorded by local medical services from January 2017 to December 2021. Additionally, a case-control study was conducted to analyze the risk factors.

**Results:** The prevalence of CAs in this study area was 6.02 per thousand births. Musculoskeletal system anomalies were the most common (32.88%), followed by nervous system anomalies (22.20%). Genital organ abnormalities represented 7.37%, and cleft lip and palate accounted for 7.03%. Analysis by type of CA revealed that clubfeet were the most commonly reported anomalies in the study area, with a prevalence of 18%, followed by spina bifida (9%), anencephaly (7%), and cleft lips and palate (7.9%). The sex ratio (males/females) for all CAs was 1.24. Risk factors identified in this study included rural residency, maternal age over 35 years, parity, consanguinity, family history of CA, medication use before and during pregnancy, and infection episodes during pregnancy.

**Conclusions:** The relatively high prevalence of congenital abnormalities in the Beni Mellal-Khenifra region highlights the need for prevention strategies through preconception care counseling and pregnancy monitoring, especially in rural areas. It is urgent to establish a teratovigilance registry in Morocco.

**Keywords:** Congenital Abnormalities, Prevalence, Risk Factors, Morocco

## 1. Background

Congenital abnormalities (CAs), also known as congenital malformations or birth defects, are structural or functional abnormalities present at or before birth, or they may be diagnosed only later in life (1). These defects constitute significant causes of infant and childhood morbidity, disabilities, and deaths, generating a real social impact and requiring long-term specialized care.

An estimated 6% of babies worldwide are born with a congenital anomaly (CA) (2). The prevalence varies by

country, with nine out of ten children born with a serious birth defect in low- and middle-income countries (3). Neural tube defects (NTDs) and Down syndrome are among the most common types of CAs (3). While the etiology of most cases remains unknown, it is multifactorial, involving both environmental and genetic factors (4). It is estimated that 30% of CAs are due to recognized genetic factors, 10% to environmental factors, and about 50% remain unexplained (5). Many risk factors have been associated with CAs, including maternal age, environmental pollution, nutrition, medications and use of herbal remedies, maternal chronic diseases, infections contracted by the mother

during pregnancy, maternal overweight and obesity, exposure to radiation, and consanguinity (5).

Prevention of some CAs is possible. Folic acid supplementation before and during the first months of pregnancy has proven effective in preventing NTDs and other CAs sensitive to folic acid, such as congenital heart defects and urinary tract anomalies (6).

Recognizing this public health issue, the Moroccan Ministry of Health and Social Protection is committed to implementing prevention programs and early detection of pathologies that cause disability (7). Several preventive measures have been taken, including the fortification of flour with folic acid since 2006, folic acid supplementation since 2008, and a policy of rubella vaccination. Additionally, neonatal screening for congenital hypothyroidism is being generalized throughout the country. Recently, screening for deafness has been implemented in the capital, Rabat, with hopes to extend it nationwide.

Understanding the epidemiological situation and risk factors is crucial for implementing specific prevention measures, thereby reducing neonatal and infant mortality and morbidity.

In Morocco, a system for notifying CAs has been in place since 2012, but it identifies only NTDs and orofacial clefts without providing details about other CAs. According to a recent study by Kannane et al. (8), based on data from the national CA surveillance system, the estimated national prevalence of CAs in Morocco is 3.91 per 1,000 live births (LBs). The study highlights a significant underestimation, noting that the majority of CAs are unspecified congenital malformations (68.55%). Other local studies based on hospital retrospective data have estimated regional prevalence rates between 0.57% and 1.02% of births (9-11). For example, between 2011 and 2014, the nervous system was the most affected system in the Rabat-Salé-Kénitra region, with a prevalence of 19.4% (9). In the same region, a 2020 study found that musculoskeletal anomalies predominated, with a rate of 33% (10). In contrast, during 2022, NTDs were the most common anomalies in the Marrakech-Safi region, with a prevalence of 3.65 per 1,000 births (11).

According to the initial situational analysis (8), the prevalence of CAs in the Beni Mellal-Khenifra region was 5.54 per 1,000 births from 2017 to 2021. However, there is currently no data on the exact regional prevalence of CAs, their distribution, or their risk factors.

## 2. Objectives

This study aims to report the prevalence of clinically visible CAs by type of anomaly, their distribution, and

their risk factors in the Beni Mellal-Khenifra region of central Morocco.

## 3. Methods

### 3.1. Study Area and Population

The study was conducted in seven health facilities providing antenatal care in the Beni Mellal-Khenifra region, located in central Morocco. This region covers an estimated area of 28,088 km<sup>2</sup> and is divided into five provinces: Beni Mellal, Fquih Ben Saleh, Azilal, Khenifra, and Khouribga (12, 13). The region reports a high number of LBs, with 28,020 recorded in 2021, representing 7.3% of the LBs recorded nationally (14). The region has one regional hospital center, four provincial hospitals, six local medical emergency centers, and 52 delivery structures distributed between rural and urban areas.

### 3.2. Data Collection

#### 3.2.1. Cross-Sectional Study

This retrospective epidemiological study was designed to include 163,842 deliveries from delivery structures between January 2017 and December 2021. Data were obtained from delivery files recorded by local medical services. Clinically detectable cases of CAs were initially screened by midwives through a systematic examination, and all cases were subsequently confirmed by pediatricians and/or general practitioners. All confirmed cases of CAs were included, regardless of whether they were born alive or stillborn, while delivery records indicating that the newborn was normal or the status was unknown were excluded. The types of birth defects were classified according to the diagnostic standards of CAs from the International Classification of Diseases (ICD-10) codes (15).

#### 3.2.2. Case-control Study

For the analytical part of the study, "cases" were defined as any newborns born after 22 weeks of amenorrhea at one of the 63 delivery structures within the study site during the study period (January 2017 to December 2021) who presented with at least one clinically visible CA. Malformed newborns were identified through a systematic examination performed by midwives, and the diagnosis was subsequently confirmed by a pediatrician and/or general practitioner. "Controls" were defined as newborns of the same sex, without any clinically visible CAs at birth, born during

the same period and at the same study site. Each identified "case" of CA was compared with three "controls."

The variables included were: Socio-demographic characteristics (such as maternal age and residence area), CAs (type and number of CAs by system and name, newborn sex and weight, etc.), and conditions of delivery (including parity, maternal disease, pregnancy monitoring, consanguinity, medication and plant intake, etc.).

### 3.3. Ethical Considerations

The researchers obtained permission from Morocco's Ministry of Health and Social Protection to collect the data (Ref. N°482/2021). The principle of anonymity was maintained in the processing of delivery records for mothers with newborns affected by congenital malformations.

### 3.4. Data Analysis

Collected data were entered and analyzed using SPSS 26 software for Windows. An exhaustive sampling approach was employed for the cases, while random sampling was used to select the controls. To achieve this, all children of the same age and sex were identified, and then three newborns were randomly chosen from among them.

A descriptive analysis was conducted to outline the characteristics of both cases and controls, followed by a bivariate analysis to identify variables for inclusion in the multivariate model.

In the multivariate analysis, conditional logistic regression with sex matching was utilized to explore factors associated with malformations. This approach was chosen for its ability to control for matching effects and minimize potential biases in estimating associations.

## 4. Results

### 4.1. Prevalence of Clinically Visible Congenital Abnormalities

In the entire region over 5 years, 1,085 out of 163,842 delivery files were found to have clinically visible malformations, resulting in an overall prevalence of 6.02 per 1,000 births. The prevalence of CAs ranges from 5.36 to 9.52 per 1,000 births depending on the province, with Khenifra reporting the lowest prevalence at 5.36 per 1,000 births, while Azilal recorded the highest prevalence at 9.52 per 1,000 births (Figure 1).

A progressive increase in annual prevalence was observed between 2017 and 2020, with the maximum annual prevalence of CAs recorded in 2020 (7.94 per 1,000 births), followed by the lowest prevalence in 2021 (5.53 per 1,000 births) (Figure 2). Similar trends were observed for spina bifida and clubfeet, while an opposite trend was noted for cleft lips.

According to the monthly distribution of CAs (Figure 3), the total number of CAs peaked in March, May, and July, and was lowest in February, June, and October. Similar variations were observed for spina bifida, clubfeet, and cleft lips.

### 4.2. Distribution of Clinically Visible Congenital Abnormalities

Among these newborns with CAs, and according to the ICD-10 classification presented in Table 1, out of 1,085 cases, 1,180 types of CAs were recorded. Of these cases, 17.14% involved polymalformations (at least two malformations), and 70% of the newborns with CAs were from rural areas. Musculoskeletal anomalies were the most common CAs, representing 32.88% of cases. The second most common anomalies were those of the nervous system, accounting for 22.20%. Abnormalities of the genital organs represented 7.37%, while cleft lip and palate accounted for 7.03%. Chromosomal anomalies were present in 5.42% of cases.

Analysis by type of CAs (Figure 4) revealed that the most frequent CA was clubfoot, found in 18% of cases, followed by spina bifida (9%), anencephaly (7%), and cleft lips and palate (7.9%). Other CAs, such as polydactyly, malformations of the hand, hypospadias, laparoshisis, and choanal atresia, represented 39% of cases. The circulatory system anomalies represented only 1.02% of cases.

Maternal factors associated with CAs included residency ( $P < 0.050$ ), maternal age over 35 years ( $P < 0.001$ ), parity ( $P < 0.05$ ), consanguinity ( $P < 0.001$ ), a family history of CAs ( $P < 0.001$ ), medication use before and during pregnancy ( $P < 0.001$ ), and infection episodes during pregnancy ( $P < 0.001$ ) (Table 2).

The results of the conditional binary regression model, which included socio-demographic and biological factors, indicated that maternal age, consanguinity, parity, maternal pathology, family history, medication taken before and during pregnancy, and infections during pregnancy played roles in the development of congenital malformations. The regression model results (Table 3) show that, in order of significance, infections during pregnancy ( $\chi^2 = 48.5$ ), family history, medication taken before and during pregnancy, and maternal age are significantly associated



**Figure 1.** Distribution of clinically visible congenital abnormalities (CAs) in the region of Beni Mellal- Khenifra

with congenital malformations. It appears that infections during pregnancy are most strongly associated with an increased risk of developing a congenital malformation.

The study found that having a family history of CAs increases the risk of birth defects by 10 times. This risk is 6 times higher for babies whose mothers suffered from infections during pregnancy, 5 times higher for those

whose mothers used medication before pregnancy, and 3 times higher for those whose mothers used medication during pregnancy. Additionally, being a woman over 35 years old increases the risk of having a malformed baby by 3 times. Similar risks were observed for multiparous mothers and for consanguineous parents.




Figure 2. Prevalence of congenital abnormalities in Beni Mellal-Khenifra from 2017 to 2021




Figure 3. Annual prevalence of congenital abnormalities in Beni Mellal-Khenifra from 2017 to 2021

### 5. Discussion

Congenital malformations are a major cause of reduced life expectancy and disability. In Morocco, CAs remain a significant health issue due to the lack of a national CA registry. Consequently, epidemiological surveillance primarily focuses on notifying NTDs and

orofacial clefts, without specifying other types of CAs. A study conducted in 2014 categorized Morocco as having modest prevention efforts for birth defects (16).


The present study aimed to prospectively investigate the prevalence, distribution, and risk factors of clinically visible CAs in the Beni Mellal-Khenifra region. Out of

**Table 1.** Number, Frequency and Prevalence of Congenital Malformations from (2017 - 2021) by System out of 163842 Births <sup>a</sup>

Malformation According to the International Classification ICD-10	Number of Births with Malformation	Prevalence per 1000B	95% CI	
			Lower	Upper
Q00-Q07 nervous system	262 (22.20)	1.60	1.597	1.602
Q10-Q18 eye, ear, face and neck	27 (2.29)	0.16	0.162	0.167
Q20-Q28 circulatory system	12 (1.02)	0.07	0.071	0.076
Q30-Q34 respiratory system	25 (2.12)	0.15	0.15	0.155
Q35-Q37 cleft lip and palate	83 (7.03)	0.51	0.504	0.509
Q38-Q45 digestive system	72 (6.10)	0.44	0.437	0.442
Q50-Q56 genital organs	87 (7.37)	0.53	0.529	0.533
Q60-Q64 urinary system	47 (3.98)	0.29	0.284	0.289
Q65-Q79 musculoskeletal system	388 (32.88)	2.37	2.366	2.371
Q80-Q89 other cas	113 (9.58)	0.69	0.687	0.692
Q90-Q99 chromosomal anomalies	64 (5.42)	0.39	0.388	0.393
<b>Total</b>	<b>1180 (100.00)</b>	<b>6.02</b>	<b>6.018</b>	<b>6.022</b>

Abbreviations: CAs, congenital abnormalities; ICD-10, International Classification of Diseases.

<sup>a</sup> Values are expressed as No. (%).



**Figure 4.** Distribution of clinically visible congenital abnormalities (CAs) by month from 2017 to 2020/2021 in the region of Beni Mellal- Khenifra

163,842 examined LBs, CAs were observed in 1,085 cases, resulting in a prevalence of 6.02 per 1,000 LBs, which is higher than the prevalence estimated for the study region by the national surveillance system (5.54/1,000 births) (8). This discrepancy may be attributed to notification omissions in some cases.

The prevalence found in our study is lower compared to the 10.2/1,000 LBs reported by Elghanmi et al. (9) for the 2011–2014 period at the Souissi Maternity in Rabat. However, our prevalence is relatively higher than the 5.58/1,000 LBs reported by Forci et al. (10) for the 2011–2016 period in Rabat. Additionally, a recent study



**Table 2.** Distribution of Cases and Controls According to Socio-Demographic, Economic and Medical Characteristics <sup>a</sup>

Variables	Cases; N = 267 (25%)	Control; N = 801 (75%)	Total	P-Value
<b>Age class (y)</b>				< 0.001
Mother ≥ 35	60 (22.5)	73 (9.1)	133	
Mother < 35	207 (77.5)	728 (22.5)	935	
<b>Residence</b>				0.005 <sup>b</sup>
Urban	74 (27.7)	156 (19.5)	230	
Rural	193 (72.3)	645 (80.5)	838	
<b>Matrimonial status</b>				0.703 nt
Single	6 (2.2)	15 (1.9)	21	
Married	261 (97.8)	786 (98.1)	1047	
<b>Consanguinity</b>				< 0.001
Yes	39 (14.6)	24 (3.0)	63	
No	228 (85.4)	777 (97.0)	1005	
<b>Parity</b>				< 0.001
Grand multiparous	10 (3.7)	44 (5.5)	54	
Multiparous	32 (12)	215 (26.8)	247	
Pupiparous	99 (37.1)	182 (22.7)	281	
Prim parous	126 (47.2)	360 (44.9)	486	
<b>Maternal pathology</b>				0.874 ns
Yes	35 (13.1)	102 (12.7)	137	
No	232 (86.9)	699 (87.3)	931	
<b>Family history of CA</b>				< 0.001
Yes	9 (1.1)	44 (16.5)	53	
No	792 (98.9)	223 (83.5)	1015	
<b>Usage of medication before pregnancy</b>				< 0.001
Yes	9 (52.9)	8 (47.1)	46	
No	241 (90.3)	781 (97.5)	1022	
<b>Usage of medication during Pregnancy</b>				< 0.001
Yes	89 (33.3)	109 (13.6)	198	
No	178 (66.7)	692 (86.4)	870	
<b>Infection during pregnancy</b>				< 0.001
Yes	133 (49.8)	82 (10.2)	215	
No	134 (50.2)	719 (89.8)	853	

Abbreviations: nt, not significant; CA, congenital anomaly.

<sup>a</sup> Values are expressed as No. (%).<sup>b</sup> P < 0.050.

conducted by our laboratory in the Marrakech-Safi region in 2022 reported a CA prevalence of 9.2/1,000 births, with NTDs being the most frequent (3.65/1,000 births), followed by musculoskeletal and digestive tract anomalies. Despite similarities in socio-demographic data (14) between the regions—such as poverty rate, urbanization rate, total fertility rate, and literacy rate—the Marrakech-Safi region exhibited a much higher prevalence. This discrepancy may be due to the Marrakech University Hospital serving multiple regions and the presence of additional risk factors that warrant further investigation.

Notably, the prevalence found in our study remains higher than the national prevalence of 3.91/1,000 LBs estimated for the same period by the national surveillance system. Similar prevalence rates were observed in other studies, such as 6.5/1,000 LBs reported by Ekwochi et al. (17) in a tertiary healthcare facility in South-East Nigeria and 0.62% reported by Mekonnen et al. (4) in Ethiopia.

The highest prevalence was recorded in Azilal province (9.52/1,000 births), known for its challenging conditions, including high poverty rates, high illiteracy

**Table 3.** Conditional Logistic Regression Model Variables and Bio Demographic and Socio-Cultural Factors

Variables	B	SD	$\chi^2$	df	P-Value	Odds Ratio (CI à 95%)
Residence (ref: Rural)	0.093	0.272	0.117	1	0.732 ns	1.097 (0.644-1.869)
Age range -mother (ref: < 35 y)	1.098	0.328	11.238	1	< 0.001	2.999 (1.578-5.698)
Consanguinity (ref: No)	1.115	0.488	5.222	1	< 0.050	3.051 (1.172-7.941)
Parity (ref: Primiparous)	1.204	0.386	9.737	1	< 0.050	3.332 (1.565-7.096)
Family history of CA (ref: No)	2.305	0.495	21.733	1	< 0.001	10.029(3.804-26.435)
Usage of medication before pregnancy (ref: No)	1.726	0.506	11.642	1	< 0.001	5.620 (0.574-39.254)
Usage of medication during pregnancy (ref: No)	1.217	0.266	20.893	1	< 0.001	3.376 (2.004-5.688)
Infections during pregnancy (ref: No)	1.792	0.257	48.510	1	< 0.001	6.000 (3.624-9.933)

Abbreviations: Ref, reference class; B, constant; SD, sum of deviations; df, degree of liberty; P, significance level of the test of  $\chi^2$ ; CI, confidence interval; CA, congenital anomaly.

rates, and limited geographical and cultural access to healthcare.

The maximum annual prevalence of CAs peaked in 2020 (7.94/1,000 births) and decreased in 2021 (5.53/1,000 births). Similar trends were observed for spina bifida and club feet, although no seasonal variations were detected in our data analysis.

In our study, the most common CAs were musculoskeletal system anomalies (32.88%), followed by nervous system anomalies (22.20%). This aligns with Forci et al. (10), who reported musculoskeletal abnormalities as the most frequent, followed by neurological abnormalities. Conversely, Elghanmi et al. (9) found that neurological abnormalities were the most common, followed by musculoskeletal abnormalities. In Nigeria, Ekwochi et al. (17) reported that more than half of the anomalies involved the musculoskeletal system. A 2020 meta-analysis by Adane et al. (18) found that musculoskeletal system defects were the most prevalent type of CA in sub-Saharan Africa (3.90/1,000 births), while Down syndrome was the least prevalent (0.62/1,000 births).

Many studies have reported that congenital heart malformations are the most common defects (19-21). In contrast, only 1.02% of the CAs detected in our study were circulatory system abnormalities, which is likely an underestimation given the prevalence of congenital heart disease. One reason for this underestimation is the difficulty in diagnosing such conditions clinically, as they are often associated with fetal asphyxia and are usually identified only after transfer to a tertiary hospital.

In our study, the most frequent congenital malformation was club feet (18%), followed by spina bifida (10%), anencephaly (7%), and cleft lip and palate (7.9%). A retrospective 21-year study conducted in Tunisia

found that limb defects were the most frequently detected malformations (22).

The high prevalence of NTDs (1.15/1,000 births) may be attributed to the consumption of fenugreek, a teratogenic plant commonly used in Morocco (23). Skalli (24) and Seddiki et al. (25) observed a correlation between the consumption of fenugreek and the occurrence of NTDs. Conversely, a 2021 Moroccan study found that there was no effective prevention of NTDs with folic acid in the preconception period, as only 41% of mothers had taken it during the first trimester of pregnancy (26).

Our study found that males are more likely to have CAs than females, a trend also observed in other Moroccan and international studies (9, 10, 27-31). However, a one-year Moroccan study by Sabiri et al. (32) found a sex ratio of 1.

Most women who gave birth to malformed newborns lived in rural areas (72.3%), where the urbanization rate is low (41%), in contrast to studies conducted in Morocco's capital where urbanization is very high. These findings suggest that in rural areas, the high prevalence of CAs can be attributed to poor living conditions, lack of hygiene, and inadequate medical monitoring during pregnancy.

Our results also indicated that mothers over 35 years old are more likely to have newborns with CAs, consistent with other studies showing that this age group is more commonly represented among mothers (9, 33, 34). However, this finding contradicts several studies (17, 35, 36) that have reported higher CA rates in mothers under 35 years. Our findings align with a study conducted in Ethiopia (4), which concluded that maternal age and residence significantly affect the risk of CAs. In addition to age, our study identified other maternal risk factors, including multiparity, consanguinity, genetic factors, medication use before



and during pregnancy, maternal pathology, and infection episodes during pregnancy. These findings highlight the need to adopt and adapt CA prevention measures contextually for greater effectiveness.

Our study is the first in the Beni Mellal-Khenifra region to provide an overview of CAs and analyze the associated risk factors. However, the prevalence in our study is likely underestimated due to the non-inclusion of abortions involving CAs; this information is not available in our context. Additionally, the study did not include home births, which account for 25% of deliveries in Morocco (37), nor did it include data from the private sector.

Based on our results, we recommend establishing a CA registry to prevent missed notifications and obtain more detailed case information. We also suggest implementing prenatal and preconception consultations, improving pregnancy monitoring, especially in rural areas, and conducting a study to identify risk factors associated with the most common malformation in our context, which is club feet.

### 5.1. Conclusions

Our study is the first to describe the epidemiology of congenital abnormalities and their risk factors in the study area. The relatively high prevalence of congenital abnormalities in our study highlights the need for improved prevention strategies, including preconception care, enhanced pregnancy monitoring, folic acid supplementation, avoidance of consanguineous marriages, and careful consideration of medication and plant use, particularly in disadvantaged areas.

### Acknowledgements

The authors thank the Regional Direction of Health Ministry and Social Protection in Beni Mellal-Khenifra for the permission to conduct the study in the region of Beni Mellal-Khenifra in Morocco; and Pr Ouzir for manuscript review and useful comments

### Footnotes

**Authors' Contribution:** S. K., S. B., I. A., J. O. and O. T., conceived the study design; S. K., I. A., J. O., collected, analyzed the data and draft the manuscript; S. B. and O. T., verified the analytical methods and reviewed the manuscript.

**Conflict of Interests Statement:** The authors have no conflict of interest to declare.

**Data Availability:** The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to data security and confidentiality.

**Ethical Approval:** The researchers obtained permission from Morocco's Ministry of Health to collect the data (Ref. N°482/2021).

**Funding/Support:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### References

1. Wonkam A. Birth defects and genetic disease in sub-saharan Africa. In: Ibrahim ME, Rotimi CN, editors. *The Genetics of African Populations in Health and Disease*. Cambridge, England: Cambridge University Press; 2019. p. 268-310.
2. World Health Organization. *Sixty-third World Health Assembly*. Geneva, Switzerland: World Health Organization; 2010. Available from: [https://apps.who.int/gb/ebwha/pdf\\_files/WHA63/REC1/WHA63\\_REC1-en.pdf?ua=1](https://apps.who.int/gb/ebwha/pdf_files/WHA63/REC1/WHA63_REC1-en.pdf?ua=1).
3. World Health Organization. *Congenital anomalies Key facts*. Geneva, Switzerland: World Health Organization; 2016. Available from: <https://www.who.int/news-room/fact-sheets/detail/congenitalanomalies>.
4. Mekonnen D, Worku W, MollaTaye. Congenital anomalies among newborn babies in Felege-Hiwot Comprehensive Specialized Referral Hospital, Bahir Dar, Ethiopia. *Sci Rep*. 2021;**11**(1):11027. [PubMed ID: 34040058]. [PubMed Central ID: PMC8154920]. <https://doi.org/10.1038/s41598-021-90387-0>.
5. Moorthie S, Blencowe H, Darlison MW, Lawn J, Morris JK, Modell B, et al. Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. *J Community Genet*. 2018;**9**(4):387-96. [PubMed ID: 30218347]. [PubMed Central ID: PMC6167261]. <https://doi.org/10.1007/s12687-018-0384-2>.
6. De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev*. 2015;**2015**(12). CD007950. [PubMed ID: 26662928]. [PubMed Central ID: PMC8783750]. <https://doi.org/10.1002/14651858.CD007950.pub3>.
7. Ministry of Health and Social in morocco protection. *International Statistical Classification of Diseases and Conditions and Related Health Problems*. 2017. Available from: [https://unece.org/sites/default/files/2023-01/ECE\\_CEP\\_191\\_E.pdf](https://unece.org/sites/default/files/2023-01/ECE_CEP_191_E.pdf).
8. Kannane S, Boussaa S, Mendili JE, Touloun O. Congenital Malformations in the Moroccan Surveillance System: Contribution to Prevalence Estimation. *Glob Health Epidemiol Genom*. 2024;**2024**:9570798. [PubMed ID: 38529480]. [PubMed Central ID: PMC10963113]. <https://doi.org/10.1155/2024/9570798>.
9. Elghanmi A, Razine R, Jou M, Berrada R. Congenital malformations among newborns in Morocco: A retrospective study. *Pediatr Rep*. 2020;**12**(1):7405. [PubMed ID: 32308967]. [PubMed Central ID: PMC7160859]. <https://doi.org/10.4081/pr.2020.7405>.
10. Forci K, Alami MH, Bouaiti E, Slaoui M, Mdaghri Alaoui A, Thimou Izgua A. Prevalence of congenital malformations at the "les Orangers" maternity and reproductive health Hospital of Rabat:

- descriptive study of 470 anomalies. *BMC Pediatr.* 2020;**20**(1):272. [PubMed ID: 32493258]. [PubMed Central ID: PMC7268369]. <https://doi.org/10.1186/s12887-020-02179-6>.
11. Adri I, Touloun O, Boussaa S. Prevalence and Risk Factors for Congenital Malformations in Morocco. *Middle East J Rehabil Health Stud.* 2024;**11**(3). e141684. <https://doi.org/10.5812/mejrh-141684>.
  12. Haut Commissariat au Plan. *Les indicateurs sociaux du Maroc.* Morocco: Haut Commissariat au Plan; 2022. p. 11-81.
  13. High Planning Commission. *Regional Monograph of Beni Mellal-Khenifra, Kingdom of Morocco.* 2018. Available from: <https://www.data4sdgs.org/partner/hcp-high-commission-planning-morocco>.
  14. Ministry of Health and Social Protection in Morocco D of P and F resources. Health in numbers. *Ministry of Health and Social Protection in Morocco D of P and F resources.* 2021;**4**:88-100.
  15. Agence technique de l'information sur l'hospitalisation. *Classification statistique internationale des maladies et des problèmes de santé connexes.* 2017. Available from: [https://www.atih.sante.fr/sites/default/files/public/content/3069/cim-10\\_fr\\_2017.pdf](https://www.atih.sante.fr/sites/default/files/public/content/3069/cim-10_fr_2017.pdf).
  16. Kancherla V, Oakley GP, Brent RL. Urgent global opportunities to prevent birth defects. *Semin Fetal Neonatal Med.* 2014;**19**(3):153-60. [PubMed ID: 24333206]. <https://doi.org/10.1016/j.siny.2013.11.008>.
  17. Ekwochi U, Asinobi IN, Osuorah DCI, Ndu IK, Ifediora C, Amadi OF, et al. Pattern of Congenital Anomalies in Newborn: A 4-Year Surveillance of Newborns Delivered in a Tertiary Healthcare Facility in the South-East Nigeria. *J Trop Pediatr.* 2018;**64**(4):304-11. [PubMed ID: 28977670]. <https://doi.org/10.1093/tropej/fmx067>.
  18. Adane F, Afework M, Seyoum G, Gebrie A. Prevalence and associated factors of birth defects among newborns in sub-Saharan African countries: a systematic review and meta-analysis. *Pan Afr Med J.* 2020;**36**:19. [PubMed ID: 32774596]. [PubMed Central ID: PMC7388615]. <https://doi.org/10.11604/pamj.2020.36.19.19411>.
  19. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. *Adv Exp Med Biol.* 2010;**686**:349-64. [PubMed ID: 20824455]. [https://doi.org/10.1007/978-90-481-9485-8\\_20](https://doi.org/10.1007/978-90-481-9485-8_20).
  20. Broe A, Damkier P, Pottegard A, Hallas J, Bliddal M. Congenital Malformations in Denmark: Considerations for the Use of Danish Health Care Registries. *Clin Epidemiol.* 2020;**12**:1371-80. [PubMed ID: 33364846]. [PubMed Central ID: PMC7751580]. <https://doi.org/10.2147/CLEP.S278596>.
  21. Giang HTN, Bechtold-Dalla Pozza S, Ulrich S, Linh LK, Tran HT. Prevalence and Pattern of Congenital Anomalies in a Tertiary Hospital in Central Vietnam. *J Trop Pediatr.* 2020;**66**(2):187-93. [PubMed ID: 31377805]. <https://doi.org/10.1093/tropej/fmz050>.
  22. Aloui M, Nasri K, Ben Jemaa N, Ben Hamida AM, Masmoudi A, Gaigi SS, et al. Congenital anomalies in Tunisia: Frequency and risk factors. *J Gynecol Obstet Hum Reprod.* 2017;**46**(8):651-5. [PubMed ID: 28539259]. <https://doi.org/10.1016/j.jogoh.2017.05.006>.
  23. Taloubi LM, Rhouda H, Belahcen A, Smires N, Thimou A, Mdaghri AA. An overview of plants causing teratogenicity: fenugreek (*Trigonella foenum graecum*). *Int J Pharmaceutical Sci Res.* 2013;**4**(2):516.
  24. Skalli S. Malformations associées à la prise de fenugrec au cours de la grossesse. *Bulletin d'informations de pharmacovigilance.* 2006;**3**(11):1-2.
  25. Seddiki AE, Messaoudi S, Amrani R. Le rôle du fenugrec dans la survenue d'anomalie de fermeture du tube neural: un signal d'alerte depuis le Maroc. *Phytothérapie.* 2017;**15**(3):155.
  26. Forci K, Bouaiti EA, Alami MH, Mdaghri Alaoui A, Thimou Izgua A. Incidence of neural tube defects and their risk factors within a cohort of Moroccan newborn infants. *BMC Pediatr.* 2021;**21**(1):124. [PubMed ID: 33722213]. [PubMed Central ID: PMC7958414]. <https://doi.org/10.1186/s12887-021-02584-5>.
  27. Radouani MA, Chahid N, Benmiloud L, El Ammari L, Kharbach A, Rjimiati L, et al. Prevalence of neural tube defects: Moroccan study 2008-2011. *Open J Pediatr.* 2015;**5**(3):248.
  28. Sokal R, Tata LJ, Fleming KM. Sex prevalence of major congenital anomalies in the United Kingdom: a national population-based study and international comparison meta-analysis. *Birth Defects Res A Clin Mol Teratol.* 2014;**100**(2):79-91. [PubMed ID: 24523198]. [PubMed Central ID: PMC4016755]. <https://doi.org/10.1002/bdra.23218>.
  29. Tennant PW, Samarasekera SD, Pless-Mulloli T, Rankin J. Sex differences in the prevalence of congenital anomalies: a population-based study. *Birth Defects Res A Clin Mol Teratol.* 2011;**91**(10):894-901. [PubMed ID: 21987467]. <https://doi.org/10.1002/bdra.22846>.
  30. Silesh M, Lemma T, Fenta B, Biyazin T. Prevalence and Trends of Congenital Anomalies Among Neonates at Jimma Medical Center, Jimma, Ethiopia: A Three-Year Retrospective Study. *Pediatric Health Med Ther.* 2021;**12**:61-7. [PubMed ID: 33628075]. [PubMed Central ID: PMC7898197]. <https://doi.org/10.2147/PHMT.S293285>.
  31. Hamilton IS, DeFranco E. 479: Gender differences in risk of major birth defects in relation to maternal body mass index. *Am J Obstetrics Gynecol.* 2020;**222**(1):S313-4.
  32. Sabiri N, Kabiri M, Razine R, Kharbach A, Berrada R, Barkat A. Facteurs de risque des malformations congénitales: étude prospective à la maternité Souissi de Rabat au Maroc. *J de Pédiatrie et de Puériculture.* 2013;**26**(4):198-203.
  33. Syvanen J, Nietosvaara Y, Hurme S, Perheentupa A, Gissler M, Raitio A, et al. Maternal risk factors for congenital limb deficiencies: A population-based case-control study. *Paediatr Perinat Epidemiol.* 2021;**35**(4):450-8. [PubMed ID: 33438777]. <https://doi.org/10.1111/ppe.12740>.
  34. Zhao L, Chen L, Yang T, Wang T, Zhang S, Chen L, et al. Birth prevalence of congenital heart disease in China, 1980-2019: a systematic review and meta-analysis of 617 studies. *Eur J Epidemiol.* 2020;**35**(7):631-42. [PubMed ID: 32519018]. [PubMed Central ID: PMC7387380]. <https://doi.org/10.1007/s10654-020-00653-0>.
  35. Mashuda F, Zuechner A, Chalya PL, Kidenya BR, Manyama M. Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical center, Mwanza, Tanzania. *BMC Res Notes.* 2014;**7**:195. [PubMed ID: 24679067]. [PubMed Central ID: PMC3974194]. <https://doi.org/10.1186/1756-0500-7-195>.
  36. Nazer J, Cifuentes L, Águila A, Ureta P, Bello MP, Correa F, et al. Edad materna y malformaciones congénitas: Un registro de 35 años. 1970-2005. *Revista médica de Chile.* 2007;**135**(11):1463-9.
  37. High Planning Commission. *Regional Monograph of Beni Mellal-Khenifra, Kingdom of Morocco.* 2017. Available from: <https://www.hcp.m>.